🧠🔬 PSMA PET: The Answer to MRI-Occult Prostate Cancer… or Another Mirage? Multiparametric MRI (mpMRI) has transformed the diagnostic pathway for prostate cancer, yet a substantial proportion of clinically significant prostate cancers (csPCa) may still remain undetected in patients with negative or equivocal MRI findings. This commentary explores the emerging role of PSMA PET/CT as a complementary imaging modality for detecting MRI-occult disease, highlighting evidence from prospective studies such as PRIMARY and PEDAL. The authors discuss how PSMA PET may improve sensitivity and negative predictive value while potentially reducing unnecessary biopsies in selected patients with persistent clinical suspicion of prostate cancer. 🧲☢️ "At the same time, important questions remain regarding the biological significance of PSMA-positive/MRI-negative lesions, optimal patient selection, cost-effectiveness, and the risk of overdetecting clinically indolent disease. These findings reinforce the growing concept that prostate cancer imaging should move beyond single-modality assessment toward a more integrated, biology-driven diagnostic framework. 🔍" - Sonja Jankovic #ProstateCancer #PSMAPET #MRI #EuropeanRadiology buff.ly/V19ocxp (Thomas Wagner et al.)

"It is imperative to define clear target audiences and implement tailored #SocialMedia strategies to reach all the possible members of the audience, across the different generations." - Melis Baykara Ulusan et al. #EuropeanRadiology 🔗 rdcu.be/dOWAN (1/2)

This guideline paper dives into the CheckList for EvaluAtion of Radiomics research (CLEAR) to improve its usability and dissemination by exploring Explanation and Elaboration with Examples for CLEAR (CLEAR-E3), a complement to CLEAR. (Burak Kocak et al.) (1/2)